Literature DB >> 9286237

Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases.

G Montalto1, A L Zignego, M I Ruggeri, C Giannini, M Soresi, M Monti, A Carroccio, G Careccia, D Di Martino, F Giannelli.   

Abstract

In this study we aimed to correlate liver histology and the presence of hepatitis C virus (HCV) viremia, genotype, and quantity of HCV genome in 19 positive and 11 RIBA II indeterminate patients presenting persistently normal ALT values over 24 months before biopsy. In addition, after biopsy serum ALT values were monitored monthly for a mean follow-up period of 24.8 months, after which patients were reevaluated for RIBA II and the presence of viremia. Sixteen patients (53%) were serum HCV-RNA-positive; 13 of them (68%) were confirmed positive and 3 (27%) indeterminate on RIBA II. Histology of the HCV-RNA-positive patients showed eight cases of CPH (one case of genotype 1a; four cases type 1b; three cases type 2), six cases of CAH (three cases type 1b, three cases type 2), one case of CLH (type not determined), and one case of normal liver (NL) (type 1b). Histology of the HCV-RNA-negative patients showed four cases of CPH, one case of CAH, two cases of CLH, and seven cases of NL. During the follow-up period nine patients (30%) presented slight increases in ALT values (< 2 x N), and in particular, flares of ALT were observed four times in the CAH and five times in the CPH patients, who were all viremic, but never in the NL subjects. These results indicate that subjects positive on RIBA II, but with persistently normal ALT values, had a high probability of being serum HCV-RNA-positive and that almost all these viremic subjects presented histologic signs of liver disease. In contrast, RIBA II indeterminate subjects had a moderate probability of being HCV-RNA-positive, but a number of these may present signs of liver disease. In both cases there was no association with genotype or HCV-RNA serum levels. The other nonviremic cases included subjects with hepatic changes going toward resolution or with normal liver in whom hepatic biopsy can be avoided. Only one case was a true carrier since he was viremic with normal liver and persistently normal ALT values.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9286237     DOI: 10.1023/a:1018813532098

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  The pathology of hepatitis C.

Authors:  P J Scheuer; P Ashrafzadeh; S Sherlock; D Brown; G M Dusheiko
Journal:  Hepatology       Date:  1992-04       Impact factor: 17.425

2.  Antibodies to hepatitis C virus in Italian blood donors.

Authors:  G Sirchia; A Bellobuono; A Giovanetti; M Marconi
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

3.  Hepatitis-C virus infection in Italy: a multicentric sero-epidemiological study (a report from the HCV study group of the Italian Association for the Study of the Liver).

Authors:  M Chiaramonte; T Stroffolini; N Caporaso; R Coppola; A Craxì; G B Gaeta; E Sagnelli; A R Zanetti
Journal:  Ital J Gastroenterol       Date:  1991-12

4.  High prevalence of hepatitis C virus infection in a small central Italian town: lack of evidence of parenteral exposure.

Authors:  T Stroffolini; M Menchinelli; G Taliani; V Dambruoso; G Poliandri; A Bozza; R Lecce; C Clementi; F M Ippolito; A Compagnoni
Journal:  Ital J Gastroenterol       Date:  1995-06

5.  Acute and chronic hepatitis revisited. Review by an international group.

Authors: 
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

6.  A retrospective study of hepatitis C virus carriers in a local endemic town in Japan. A possible presence of asymptomatic carrier.

Authors:  S Ohkoshi; H Tawaraya; K Kuwana; T Harada; M Watanabe; S Higuchi; H Kojima; T Kamimura; H Asakura
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

7.  Hepatitis C virus RNA and liver histology in blood donors reactive to a single antigen by second-generation recombinant immunoblot assay.

Authors:  A Zanella; D Conte; D Prati; F Mozzi; C Capelli; F Zanuso; M Fraquelli; P Bosoni; L Vianello; M Pappalettera
Journal:  Hepatology       Date:  1995-04       Impact factor: 17.425

8.  Reinfection of liver graft by hepatitis C virus after liver transplantation.

Authors:  C Féray; D Samuel; V Thiers; M Gigou; F Pichon; A Bismuth; M Reynes; P Maisonneuve; H Bismuth; C Bréchot
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

9.  Serum hepatitis C virus RNA levels and liver injury in volunteer blood donors.

Authors:  N Yuki; N Hayashi; T Takehara; H Hagiwara; N Hiramatsu; M Naito; Y Kawanishi; K Katayama; A Kasahara; H Fusamoto
Journal:  Am J Gastroenterol       Date:  1994-09       Impact factor: 10.864

10.  Distribution of three major hepatitis C virus genotypes in Italy. A multicentre study of 495 patients with chronic hepatitis C.

Authors:  P Pontisso; M G Ruvoletto; M Nicoletti; S Tisminetzky; M Gerotto; M Levrero; M Artini; M Baldi; G Ballardini; L Barbara
Journal:  J Viral Hepat       Date:  1995       Impact factor: 3.728

View more
  3 in total

1.  Circulating E-selectin levels in chronic hepatitis C patients with normal or elevated transaminase before and after alpha-interferon treatment.

Authors:  G Montalto; L Giannitrapani; M Soresi; L Virruso; D D Martino; R Gambino; A Carroccio; M Cervello
Journal:  Inflammation       Date:  2001-04       Impact factor: 4.092

2.  Evaluation of The Federal Bureau of Prisons protocol for selection of which hepatitis C-infected inmates are considered for treatment.

Authors:  Monica M Pradhan; Ronald Horswell; Glenn Jones; Jennifer L Ramsey; William Cassidy
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

3.  Acetylcysteine therapy for chronic hepatitis C: are its effects synergistic with interferon alpha? A pilot study.

Authors:  S Tripi; G D Gaetano; M Soresi; A Carroccio; G Bonfissuto; A Savi; O Vuturo; G Montalto
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.